Loading…
← Back to schedule
Panel: Pharma’s Financial Landscape: Revenue Trends, M&A Strategies, and Patent Expirations
Thursday January 23, 2025 1:40pm - 2:20pm EST
Virtual
With some of the industry’s top drugs moving toward patent cliffs later this decade, Big Pharma dealmakers have remained active despite economic uncertainties. The 2024 buyouts of Catalent, Alpine Immune Sciences and CymaBay Therapeutics—among others—showed that drugmakers were willing to strike deals for the right assets at the right prices. As the industry navigates the Inflation Reduction Act and other factors, biopharma leaders and venture capitalists on this panel will share their expectations for the year ahead.
Moderators
avatar for Fraiser Kansteiner

Fraiser Kansteiner

Staff Writer, Fierce Pharma
Fraiser Kansteiner is a staff writer at Fierce Pharma. He joined the Fierce team in 2020 and covers topics such as manufacturing, COVID-19 and drug delivery. He also manages Fierce Biotech and Fierce Pharma’s LinkedIn showcase pages. Before diving into pharma reporting, Fraiser... Read More →
Speakers
avatar for Adam Pearson

Adam Pearson

Chief Strategy Officer, Astellas
As Chief Strategy Officer of Astellas Pharma, Adam Pearson plays a pivotal role in shaping the company’s corporate strategy, spearheading initiatives in business planning, the development and execution of Primary Focus strategies, business partnerships, Rx+ business creation, Patient... Read More →
avatar for Greg Graves

Greg Graves

Senior Partner, McKinsey & Company
Greg is a senior partner in McKinsey’s Life Sciences Practice, where he leads the practice’s strategy and corporate finance work. Greg focuses on defining winning corporate strategies in the face of industry disruption and market uncertainties. He works with companies across the... Read More →
avatar for Christine (Chris) Fox

Christine (Chris) Fox

Executive Vice President, U.S. Commercial, Teva Pharmaceuticals
Christine (Chris) Fox was appointed Executive Vice President, U.S. Commercial on November 20, 2023, leading all commercial activities for Teva in the U.S., including Teva’s generics, biosimilars and innovative medicines business. Chris brings more than 30 years of healthcare industry... Read More →
avatar for Jeb Keiper

Jeb Keiper

CEO & President, Nimbus Therapeutics, LLC
Jeb Keiper, MS, MBA, is CEO and president of Nimbus Therapeutics, LLC, a Boston-based biotechnology company focused on developing breakthrough medicines for patients through precision small molecule design. Jeb has overseen the discovery and development of multiple programs into clinical... Read More →
avatar for Anis Ha

Anis Ha

SVP, Deputy General Counsel Transactions and Contracting, Eli Lilly and Company
Anis Ha serves as the Senior Vice President / Deputy General Counsel of Transactions and Contracting at Eli Lilly and Company. Anis is a broadly experienced executive with global pharmaceutical, biotechnology, and law firm experience. In his current role at Eli Lilly, Anis leads a... Read More →
Thursday January 23, 2025 1:40pm - 2:20pm EST
Virtual
  Panel

Log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Share Modal

Share this link via

Or copy link